National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2016. S4.1.1-52. Sood MM, Komenda P, Sood AR, et al. The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis? Chest. 2009;136:1128 33. S4.1.1-53. Nochaiwong S, Ruengorn C, Awiphan R, et al. Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis. Open Heart. 2016;3:e000441. S4.1.1-54. Deal EN, Pope H, Ross W. Apixaban use among patients with severe renal impairment. Ann Pharmacother. 2014;48:1667. S4.1.1-55. Stanton BE, Barasch NS, Tellor KB. Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment. Pharmacotherapy. 2017;37:412 9. S4.1.1-56. Mavrakanas TA, Samer CF, Nessim SJ, et al. Apixaban pharmacoki- netics at steady state in hemodialysis patients. J Am Soc Nephrol. 2017;28:2241 8. S4.1.1-57. Reed D, Palkimas S, Hockman R, et al. Safety and effectiveness of apixaban compared to warfarin in dialysis patients. Res Pract Thromb Haemost. 2018;2:291 8. S4.1.1-58. Fauchier L, Clementy N, Bisson A, et al. Should atrial fibrillation patients with only 1 nongender-related CHA2DS2-VASc risk factor be anticoagulated? Stroke. 2016;47:1831 6. S4.1.1-59. Dias C, Moore KT, Murphy J, et al. Pharmacokinetics, pharmacody- namics, and safety of single-dose rivaroxaban in chronic hemodialy- sis. Am J Nephrol. 2016;43:229 36. CLINICAL STATEMENTS AND GUIDELINES S4.1.1-60. De Vriese AS, Caluw R, Bailleul E, et al. Dose-finding study of riva- roxaban in hemodialysis patients. Am J Kidney Dis. 2015;66:91 8. S4.1.1-61. Chan KE, Edelman ER, Wenger JB, et al. Dabigatran and rivaroxa- ban use in atrial fibrillation patients on hemodialysis. Circulation. 2015;131:972 9. S4.1.1-62. Van de Werf F, Brueckmann M, Connolly SJ, et al. 